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Abstract 
Purpose: To prepare and evaluate bioadhesive buccal films of diltiazem hydrochloride (a L-type 
calcium channel blocker) for overcoming the limitations of frequent dosing, low bioavailability and 
gastrointestinal discomfort of oral delivery.  
Methods: Buccal films were prepared by solvent casting technique using sodium 
carboxymethylcellulose, polyvinyl pyrrolidone K-30 and polyvinyl alcohol. The films were evaluated for 
weight, thickness, surface pH, swelling index, in vitro residence time, folding endurance, in vitro release, 
ex-vivo permeation (across porcine buccal mucosa) and drug content uniformity.  
Results: The drug content of the formulations was uniform with a range of 18.94 ± 0.066 (F2) to 20.08 ± 
0.07 mg per unit film (F1). The films exhibited controlled release ranging from 58.76 ± 1.62 to 91.45 ± 
1.02 % over a period > 6 h. The films containing 20 mg diltiazem hydrochloride, polyvinyl alcohol (10 %) 
and polyvinyl pyrrolidone (1 % w/v) i.e. formulation F5, showed moderate swelling, convenient 
residence time and promising drug release, and thus can be selected for further development of a 
buccal film for potential therapeutic uses. 
Conclusion: The developed formulation is a potential bioadhesive buccal system for delivering 
diltiazem directly to systemic circulation, circumventing first-pass metabolism, avoiding gastric 
discomfort and improving bioavailability at a minimal dose. 
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In recent years, mucoadhesive drug delivery 
systems (MDDSs) have been found to be very 
promising for effective and improved systemic or 
local drug delivery of variety of drugs. MDDSs 
deliver the drug through various different mucosa 
(including oral/buccal, nasal, vaginal or rectal) 
and hence prevent hepatic first pass metabolism, 
provide prompt action, reducing gastrointestinal 
irritation and reducing dosage frequency [1]. 
  
The concept of mucoadhesion may be defined as 
the intimate contact of a biomaterial or mucous 
membrane and drug delivery device for extended 
period of time [2,3]. The mucoadhesion is 
mediated with swelling, branch entanglement 
between mucosa and MDDS followed by 
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diffusion across the mucosa. The buccal mucosa 
is one of the most suitable sites for MDDS [2,4-
8].  Attempts have been made to formulate 
various mucoadhesive devices including tablets, 
films, patches, disks, strips, ointments and gels 
[9-16]. Buccal film may be preferred over 
adhesive tablet in terms of flexibility and comfort. 
In addition, they can circumvent the relatively 
short residence time of oral gels on the mucosa, 
which are easily washed away and removed by 
saliva. Moreover, the buccal films are able to 
protect the wound surface, thus reducing pain 
and treating oral diseases more effectively [17]. 
  
Diltiazem hydrochloride is a widely used 
cardiovascular drug, for the treatment of angina, 
essential hypertension and atrial flutter [18,19]. 
When administered orally, frequent dosing is 
needed due to short biological half-life (t1/2, 4 h). 
It also undergoes high hepatic first pass 
metabolism leading to low bioavailability (40 %). 
It has also been reported to cause 
gastrointestinal discomfort. Buccal route of drug 
administration may be a promising approach to 
overcome the above problems. Thus the present 
work deals with the formulation and 
characterization of mucoadhesive buccal films of 







Diltiazem hydrochloride, polyvinyl pyrrolidone K-
30 (PVP), polyvinyl alcohol (PVA) and sodium 
carboxymethylcellulose, 1500-400cps (SCMC) 
were procured from Sigma Aldrich US. All other 
reagents used were of analytical grade.  
 
Preparation of bioadhesive buccal films 
 
Buccal films of diltiazem hydrochloride were 
prepared by solvent casting technique employing 
aluminum foil cups (placed on glass surface) as 
substrate [2]. Composition of a circular cast film 
of various formulations is mentioned in Table 1. 
 
The mucoadhesive films were prepared using 
ionic (SCMC), non-ionic (PVA) and water-soluble 
(PVP) polymers. PVP was added in 
concentrations of 1 and 5 % w/v in the 
formulations to improve film performance and 
release characteristics. 
 
For SCMC (3 % w/v), the calculated amount of 
the polymer was dispersed in three forth volume 
of water with continuous stirring using 
mechanical stirrer and the final volume was 
adjusted with distilled water. In case of PVA 
films, PVA powder (10 % w/v) was dissolved in 
hot water at approximately 80 – 100 oC with 
stirring. Two percent w/v diltiazem was 
incorporated in the polymeric solutions after 
levigation with 5 % v/v glycerol added as a 
plasticizer. The medicated gels were left 
overnight at room temperature to ensure clear, 
bubble-free gels. The gels were cast into 
aluminum foil cup (4.5 cm diameter), placed on a 
glass surface and allowed to dry in a leveled 
oven maintained at 400, till a flexible film was 
formed. The dried films were cut into films of 20 
mm diameter, packed in aluminum foil and stored 
in a desiccator until further use. 
 
Evaluation of mucoadhesive buccal films 
 
For evaluation of film weight three films of each 
formulation were taken and weighed individually 
in digital balance. The average weights were 
calculated. Three films of each formulation were 
taken and the film thickness was measured using 
Micrometer Screw Gauge (Mitutoyo MMO-25DS) 
at three different places and the mean value was 
calculated. For determination of surface pH three 
films of each formulation were left to swell for 2 h 
on the surface of an agar plate. The surface pH 
was measured by means of a pH paper placed 
on the surface of the swollen patch. A mean of 
three readings was recorded. After determination 
of the original film weight and diameter, the 
samples were allowed to swell on the surface of 
agar plate kept in an incubator maintained at 37 
oC. Increase in the weight or diameter of the films 
(n = 3) was determined at preset time intervals. 
Swelling (S) was calculated as in Eq 1. 
Table 1: Composition of bioadhesive buccal films of diltiazem hydrochloride 
 
Ingredient (%w/v) F1 F2 F3 F4 F5 F6 
DILTIAZEM 
HYDROCHLORIDE 2 2 2 2 2 2 
Sodium carboxymethyl-
cellulose (1500-400cps) 3 3 3 - - - 
Polyvinyl alcohol  - - - 10 10 10 
Polyvinylpyrrolidone K-30 0 1 5 0 1 5 
Glycerol (%v/v) 5 5 5 5 5 5 
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S (%) = {(Xt – Xo)/Xo}100 ……………………. (1)  
 
where Xt and Xo are the weights of the swollen 
film after time t and initial film weight at zero time, 
respectively.  
 
Folding endurance was determined by 
repeatedly folding a small strip of film of size (2 × 
2 cm)  at the same place till it broke (n = 3). The 
number of times, the film could be folded at the 
same place without breaking gave the value of 
folding endurance [2,3,9]. 
 
Drug content assay 
 
Three film units of each formulation were taken in 
separate 100 ml volumetric flask, added 100 ml 
of pH 6.6 phosphate buffer and kept for 24 h 
under constant stirring. The solutions were 
filtered, diluted suitably and analyzed at 237 nm 
in a UV spectrophotometer (n = 3). 
 
Evaluation of in vitro residence time 
 
The in vitro residence time was determined using 
IP disintegration apparatus. The disintegration 
medium was composed of 800 ml pH 6.6 
phosphate buffer (PB) maintained at 37 ± 2 oC. 
The segments of rat intestinal mucosa, 3 cm 
length, were glued to the surface of a glass slab, 
vertically attached to the apparatus. Three 
mucoadhesive films of each formulation were 
hydrated from one surface using pH 6.6 PB and 
then the hydrated surface was brought into 
contact with the mucosal membrane.  
 
The glass slab was vertically fixed to the 
apparatus and allowed to move up and down. 
The film was completely immersed in the buffer 
solution at the lowest point and was out at the 
highest point. The time required for complete 
erosion or detachment of the film from the 
mucosal surface were recorded (n = 3). 
 
In vitro release studies 
 
The USP XXIV six station dissolution apparatus 
type 1 was used throughout the study. One Film 
of each formulation was fixed to the central shaft 
using a cyanoacrylate adhesive. The dissolution 
medium consisted of 900 ml pH 6.6 phosphate 
buffer (PB). The release study was performed at 
37 ± 0.5 oC with a rotation speed of 50 rpm. The 
release study was carried out for 6 h. After every 
one-hour, samples were withdrawn from each 
station, filtered, diluted suitably and then 
analyzed spectrophotometrically at 237 nm. The 
data presented are the mean of three 
determinations. 
 
Ex-vivo permeation studies 
 
The animal study protocols were approved by the 
Animal Ethical Committee of Qingdao University, 
Qingdao (approval no. 201483222). The studies 
were carried out in compliance with Directive 
2010/63/EU on the handling of animals used for 
scientific purposes [20]  
 
The ex-vivo permeation studies of mucoadhesive 
buccal films of diltiazem hydrochloride (through a 
thick excised layer of porcine buccal mucosa) 
were studied using the modified Franz diffusion 
cell. A 2.0 cm diameter film of each formulation 
under study was placed in intimate contact with 
the excised porcine buccal mucosa and the 
topside was covered with aluminum foil as a 
backing membrane. Teflon bead was placed in 
the receptor compartment filled with 25 ml of pH 
7.4 phosphate buffer. The cell contents were 
stirred with a magnetic stirrer and temperature of 
37 ± 10 was maintained throughout the 
experiment. Samples were withdrawn at every 
one hour, filtered, diluted suitably and then 




Results are expressed as mean ± standard 
deviation (SD). Statistical analysis was carried 
out using analysis of variance (ANOVA) on 
GraphPad Prism© 4.0 (Graphpad Software Inc. 





Mucoadhesive buccal films of diltiazem 
hydrochloride were prepared using 
mucoadhesive polymers SCMC, PVP and PVA. 
The drug delivery system was designed as a 
matrix. The physical characteristics as well as 
the bioadhesive performance of various films are 
given in Table 2.  
 
It was found that film thickness were in the range 
of 0.49 ± 0.28 to 0.99 ± 0.74 mm and weight in 
the range of 116 ± 1.86 to 129 ± 0.77 mg. 
Surface pH of the films was in the range of 5-6. 
 
The effect of diltiazem hydrochloride on the 
swelling behaviour and the residence time of the 
mucoadhesive polymers were observed (Table 
2). The folding endurance was measured 
manually, films were folded repeatedly till it 
broke, and it was considered as the end point. 
Folding endurance were found to be high (470 ± 
5) for F6 and low (189.96 ± 4.04) for F3. 
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Table 2: Physicochemical characteristics of bioadhesive buccal films of diltiazem hydrochloride 
 









endurance Drug loading (mg) 
F1 129±0.771 0.49±0.28 60.14±1.35 2.5±0.559 320.0±7.81 20.08±0.07 
F2 116 ±1.86 0.55±0.13 79.36±1.84 2.5±0.721 279.66±5.5 18.94±0.06 
F3 119±2.63 0.52±0.34 51.85±2.54 3.0±0.908 189.96±4.0 19.14±0.05 
F4 117±1.74 0.98±0.36 28.67±1.42 3.25±0.087 262.33±3.5 19.92±0.01 
F5 126±1.93 0.83±0.54 26.01±1.57 3.75±0.109 209.33±9.0 19.85±0.02 
F6 122±2.04 0.99±0.74 25.41±1.23 1.25±0.192 470.0±5.0 19.59±0.03 
 
Drug content in formulations was uniform with a 
range of 18.94 ± 0.066 (F2) to 20.08 ± 0.07 (F1). 
In vitro release studies of various formulations 
were performed in pH 6.6 phosphate buffer at 
237 nm. After 6 h the release was found to be 
91.45, 79.89, 73.65, 31.02, 58.76 and 40.45 % in 
formulation F1, F2, F3, F4, F5 and F6, 
respectively (Figure 1). 
 
 
Figure 1: Cumulative percent drug release in pH 6.6 
phosphate buffer; Formulation F1 (◦), F2 (*), F3 (×), F4 
(▲), F5 (□), F6 (◊) 
 
Among the SCMC films, F1 (SCMC 3 %) showed 
the good release. On the other hand, out of the 
PVA films, release rate was found to be higher 
for film containing 1 % w/v PVP. The plots of log 
cumulative percent drug retained versus time 
were found to be linear to the formulations 
(Figure 2). On the basis of plots it was concluded 
that the release of diltiazem from the films have 
obeyed first order kinetics. The correlation 
coefficient values were found to be -0.9963, -
0.9879, -0.9980, -0.9922, -0.9886, -0.9875 for 
F1, F2, F3, F4, F5 and F6, respectively. It shows 
that data are in good correlation. Negative values 
of the correlation coefficient indicate negative 
slope for the plot. 
 
 
Figure 2: Log cumulative % drug retained in the 






Figure 3: Higuchi plot of the formulations. Key: F1 (◦), 
F2 (*), F3 (×), F4 (▲), F5 (□), F6 (♦) 
 
Mechanism of drug release pattern i.e. diffusion, 
swelling or erosion was confirmed by Higuchi 
plots. Figure 3 shows the graphical 
representation of cumulative percentage drug 
release versus square root of time. The Higuchi’s 
Plots were found to be linear with correlation 
coefficient values of 0.9959, 0.9879, 0.9980, 
0.9922, 0.9886, 0.9875 for F1, F2, F3, F4, F5 
and F6, respectively. It was concluded that the 
release of drug from the films followed the 
diffusion controlled mechanism in all the 
formulations. 
 
It was also concluded that among the SCMC 
films formulation F1 showed the promising 
release pattern as compared to others. From the 
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PVA films formulation F5 showed moderate 
swelling, a convenient residence time as well as 
adequate drug release. On the basis of release 
pattern, swelling and residence time F1 and F5 
formulations were selected for ex vivo study. In 
ex vivo study, drug permeation through the 
porcine buccal mucosa was observed for 
formulation F1 and F5 (Figure 4). 
 
 
Figure 4: Ex-vivo permeation of diltiazem 
hydrochloride films in pH 7.4 phosphate buffer.  
Key: F1 (◊) containing SCMC 3 % w/v; F5 (□) 
containing PVA (10 %) and PVP (1 % w/v) and 
diltiazem (20 mg) 
 
The drug permeation was found to be 58.25 and 
49.01 % in F1 and F5 after 10 h. The Higuchi 
plots of F1 and F5 were almost linear with 





The medicated films showed high swelling values 
compared to plain films because of the water-
soluble drug, which enhanced the water uptake 
capacity in the finished dosage form. The 
influence of drug on the swelling properties of 
polymer matrices is primarily dependent on the 
substituted groups of the polymer. The hydroxyl 
group in the molecules played an important role 
in the matrix integrity of the swollen hydrophilic 
cellulose matrices. SCMC containing films 
showed higher percent swelling as compared to 
PVA films due to presence of more hydroxyl 
group in the SCMC molecules. The amount and 
properties of the incorporated drug determine 
matrix integrity.  
 
The incorporation of the drug induced significant 
reduction of the residence time of the studied 
formulae. The enhanced erosion rate observed 
with the non-ionic polymers PVA may correlate 
with the increase in swelling behaviour when the 
drug was added. As the particle swells, the 
matrix experiences intra-matrix swelling force 
promoting disintegration and leaching of the drug 
leaves behind a highly porous matrix. Water 
influx weakens the network integrity of the 
polymer, the structural resistance of the swollen 
matrices is thus greatly influenced and erosion of 
the lose gel layer is more pronounced [21]. The 
early dislodgment of the film from the mucosal 
surface was more distinct with the ionic polymer 
SCMC. The addition of PVP predominantly 
decreased the swelling characteristics of the 
medicated films of PVA. The water-soluble 
hydrophilic additive dissolves rapidly introducing 
porosity. The void volume is thus expected to be 
occupied by the external solvent diffusing into the 
film and thereby accelerating the dissolution of 
the gel [22]. 
 
On the basis of drug content determination it was 
considered that the drug was dispersed uniformly 
throughout the film. Significant difference was 
obtained in the release pattern of diltiazem films 
containing PVA and SCMC. During dissolution 
SCMC containing films swelled forming a gel 
layer on the exposed film surfaces. The loosely 
bound polymer molecules were easily eroded, 
allowing the release of diltiazem easily as 
compared to PVA [23]. Both polymers exhibited 
high swelling, the film weight of these polymers 
were increased by 25 to 60 % from the initial 
weight within 2 h (Table 2). Although the marked 
increase in surface area during swelling can 
promote drug release, the increase in diffusion 
path length of the drug may paradoxically delay 
the release. In addition, the thick gel layer formed 
on the swollen film surface is capable of 
preventing matrix disintegration and controlling 
additional water penetration [15].  
 
SCMC showed high dissolution rate as 
compared to PVA. It was found that the drug 
release from the prepared films varied with 
respect to the proportion of polymers. Increase in 
the polymer concentration reduces the diffusion 
of drug from the matrix. Out of the six 
formulations, the formulation F1 showed the 
good release pattern as compared to others and 
optimum sustained release profile was obtained 
in formulation F5. So both these formulations 
only were selected for ex vivo permeation 
studies. It was observed that the drug 




Bioadhesive buccal films of diltiazem have been 
successfully developed as an effective 
alternative approach for delivering the drug 
directly to systemic circulation, and thus, 
circumventing first pass metabolism, avoiding 
gastric discomfort and improving bioavailability at 
minimal dosage. The films, however, require 
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